Stocks and Investing
Stocks and Investing
Mon, March 14, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, March 11, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Jason Butler Maintained (VRDN) at Buy with Decreased Target to $31 on, Mar 11th, 2022
Jason Butler of JMP Securities, Maintained "Viridian Therapeutics, Inc." (VRDN) at Buy with Decreased Target from $36 to $31 on, Mar 11th, 2022.
Jason has made no other calls on VRDN in the last 4 months.
There is 1 other peer that has a rating on VRDN. Out of the 1 peers that are also analyzing VRDN, 0 agree with Jason's Rating of Hold.
This is the rating of the analyst that currently disagrees with Jason
- Thomas Smith of "SVB Leerink" Initiated at Buy and Held Target at $32 on, Thursday, November 18th, 2021
Contributing Sources